Algo version: 0.98b
CATB is listed at the NASDAQ Exchange
CATB [CATB]
NASDAQ Sector: Healthcare Industry:Biotechnology

Is CATB stock a buy?

What Is The Conclusion?

Right now our advanced algorithms say:

Do the analyst corps agree?

Interesting Questions and Easy Answers!

We cannot find any recorded dividends paid in our systems.

Sorry, we do not have any analyst data for this ticker

We cannot find data for Catabasis Pharmaceuticals 10 years ago, but if you had invested on Thursday 25th of June 2015 when the price was $13.00, you would have made a loss of $-4.46 per share or -34.31%

Yes, the average daily trading liquidity for Catabasis Pharmaceuticals is $2.23 million. You should therefore be able to get in and out of your positions relatively fast.

Catabasis Pharmaceuticals has N/A of the business financed by loans. This puts the company at N/A risk in periods of high inflation where borrowing costs usually go up. With a N/A cash flow to debt ratio of 0, the company's ability to pay off the debt is N/A. The company is still not profitable, and high inflation will make it harder to become profitable as costs increase and consumer spending decreases.

We have calculated the inflation risk for Catabasis Pharmaceuticals to be low [0 out of 1]